Merck, Pfizer execs explain how they tap sites for cancer trials

The decisions hinge on a trial's phase and tumor type but are also affected by certain medical experts and the companies' history with a site.

By Jacob Bell • Sept. 23, 2019

Does disclosure of pharma payments harm patient trust in doctors?

A counterintuitive finding raises questions about how transparency can be better managed, University of Pennsylvania researcher Genevieve Kanter told BioPharma Dive.

By Andrew Dunn • Sept. 23, 2019

Explore the Trendline➔

Alzheimer's disease

Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

By BioPharma Dive staff

Is the future of diabetes treatment better drugs or better care?

Drug manufacturers are trying to push the boundaries of glucose control, but cost concerns could rein in ambitions.

By Jonathan Gardner • Sept. 23, 2019

Facing $4B in claims, Insys doubts ability to pay out via Chapter 11

The bankrupt opioid drugmaker disclosed it does not expect to be able to meet "by a wide margin" the more than 8,000 outstanding claims against it.

By Andrew Dunn • Sept. 20, 2019

The top drugs facing cuts under Pelosi's pricing plan

Democrats' plan would put pressure on top-sellers from Bristol-Myers Squibb, Regeneron and Merck & Co, among others.

By Jonathan Gardner • Sept. 20, 2019

J&J finds competitive edge with latest Erleada approval

The advantage may be short-lived, however, as a rival prostate cancer drug from Pfizer could notch a similar approval in the fourth quarter.

By Jacob Bell • Sept. 18, 2019

Ebola vaccine from Merck takes step toward US approval

As DRC's outbreak persists, Merck plans to increase supply of its experimental V920 drug, aiming to produce 650,000 doses over the next six to 18 months.

By Ned Pagliarulo • Sept. 17, 2019

Opioid giant Purdue files for bankruptcy to pay for sweeping settlement

The Chapter 11 filing is meant to facilitate a more than $10 billion agreement in principle that the company just reached with 24 states and five U.S. territories.

By Jacob Bell • Sept. 16, 2019

Novartis' strong MS results could pose challenge to Roche

Little used in cancer, ofatumumab could find a second life as a multiple sclerosis drug, posting data that show it convincingly beat out Aubagio. 

By Ned Pagliarulo • Sept. 13, 2019

Private equity firm to buy Sanofi's oldest plant in India

Advent International snagged Sanofi's generics unit for $2 billion last year. Now, that unit is ready to acquire the Indian plant for about $37 million.

By Kristin Jensen • Sept. 12, 2019

Mallinckrodt selling CDMO business for up to $250M

The deal gives needed cash to Mallinckrodt, which is under pressure for its role in the opioid epidemic, and provides another example of private equity's interest in contract manufacturing.

By Kristin Jensen • Sept. 12, 2019

Public trust in drugmakers is at an all-time low. Can biopharma recover?

Leaders are grappling with how to improve the industry's reputation at a time when the broader business world is under increased scrutiny.

By Andrew Dunn • Sept. 11, 2019

Drug companies pay for exclusive access to UK genetic data

Amgen, AstraZeneca, GSK and J&J will get nine months to pour over the first wave of whole genome data coming out of UK Biobank before the global research community gets a chance to look.

By Jacob Bell • Sept. 11, 2019

Sanofi paying Lexicon $260M to exit diabetes alliance

Lexicon had argued Sanofi violated the companies' contract when providing notice in July that it would terminate a research partnership on Zynquista.

By Ned Pagliarulo • Sept. 11, 2019

Medicare would negotiate prices for 250 drugs under House Democrats' plan

Speaker Nancy Pelosi's proposal also finds common ground with the president in pegging U.S. prices to an international index.

By Jonathan Gardner • Sept. 10, 2019

Biomarker data help Merck case for wide use of Keytruda combo

"In the setting of chemo combinations, it does not appear that PD-L1 or TMB influences the outcome," said Merck development head Roy Baynes.

By Ned Pagliarulo • Sept. 10, 2019

Pfizer touts successor to Prevnar 13

Phase 2 data showed Pfizer's experimental pneumococcal vaccine to be safe, boosting confidence in what Pfizer hopes will be a follow-on to Prevnar 13.

By Andrew Dunn • Sept. 9, 2019

After scandal, Novartis pledges faster action on data integrity

CEO Vas Narasimhan committed to informing the FDA within five business days of any credible data integrity issues tied to a pending drug application.

By Ned Pagliarulo • Sept. 9, 2019

Cancer drug data back up Lilly's Loxo buyout

Updated study results show striking efficacy for LOXO-292 in an uncommon form of lung cancer, clearing the path for Lilly to file for approval this year. 

By Ned Pagliarulo • Sept. 9, 2019

Mallinckrodt plunges after report it's mulling bankruptcy amid opioid trial

Staring down more than 2,000 opioid lawsuits, the pharma has maxed out its borrowing capacity, raising the possibility of bankruptcy, per Bloomberg. 

By Andrew Dunn • Sept. 5, 2019

Pharma's reputation among Americans sinks to lowest level in decades: poll

According to Gallup, Americans even view the federal government more favorably than biopharma, which ranks as the most poorly regarded industry.

By Kristin Jensen • Sept. 4, 2019

Skyrizi looks ready to soar after strong launch

Dermatologists expect Skyrizi prescriptions to accelerate, according to a new survey that has some analysts now forecasting $300 million in 2019 sales for the psoriasis drug.

By Jacob Bell • Sept. 4, 2019

Novartis vies for multiple sclerosis dominance with Arzerra trial

The repurposed cancer drug is aiming at Roche's Ocrevus, but an upcoming full data presentation will tell MS specialists more about its promise.

By Jonathan Gardner • Aug. 30, 2019

AbbVie ends Rova-T research after another study setback

A string of clinical failures derailed AbbVie's ambitions for the cancer drug, which was once predicted to earn billions of dollars in peak sales.

By Andrew Dunn • Aug. 29, 2019

Purdue offering as much as $12 billion to settle opioid claims: report

The Oxycontin maker would reportedly declare Chapter 11 bankruptcy, becoming a public trust in which profits from drug sales would go to plaintiffs.

By Ned Pagliarulo • Aug. 28, 2019